martes, 1 de mayo de 2018

Penthrox® (metoxiflurano) Analgesico Inhalado de uso en EMS "PreHospitalario"



Penthrox® (metoxiflurano) Analgesico Inhalado de uso en EMS "PreHospitalario"

Líder en el alivio inmediato del dolor
Penthrox® (metoxiflurano) es un analgésico por inhalación “no narcótico” con importantes beneficios frente a las opciones tradicionales de alivio del dolor. Penthrox® aliviar el dolor en todos los servicios de ambulancias de Australia, en las Fuerzas Armadas australianas y neozelandesas y en otras instituciones internacionales y poco a poco en más servicios a nivel Internacional.
Hasta la fecha, Penthrox® está siendo utilizado ampliamente por los profesionales de la salud en Australia facilitando un inicio rápido de la analgesia en gran variedad de áreas clínicas, incluyendo:
  • Pre-hospitalario y emergencia (ambulancias, militar, salvamento y rescate)
  • Hospital (accidentes y emergencias, quemados, radiología, oncología)
  • Especialistas (odontología, cirugía estética, podología, flebología)
  • Intervenciones (procesos no invasivos e invasivos)
  • Primeros auxilios (pistas de ski, deportes)
El control del dolor es un componente crítico en la atención del paciente y un componente vital de la atención traumatológica. Este requisito se acentúa en situaciones militares.
En resumen, Penthrox®:
  • Aporta una analgesia rápida y efectiva (similar al efecto de los narcóticos intranasales) 
  • Posee un perfil demostrado de seguridad y eficacia (incluyendo más de 30 años de utilización en los servicios de ambulancias australianas y las Fuerzas Armadas australianas) 
  • Es un no-narcótico con muy limitado potencial de abuso.
  • Es auto-administrado por inhalación y sencillo de usar.
  • Los resultados no muestran efectos secundarios significativos.
  • No provoca depresión del sistema cardiovascular ni del sistema respiratorio
  • Requiere un entrenamiento mínimo
  • Es de un solo uso para evitar infecciones cruzadas.
  • Incorpora una tecnología de barrido para minimizar las concentraciones ambientales
  • Es ligero, portátil y fácil de almacenar.
  • Proporciona un alivio de dolor de hasta varias horas (cuando se usa de forma intermitente) 
  • Puede administrarse fácilmente de forma masiva en grandes siniestros o situaciones de emergencia
Se han administrado más de 2 millones de unidades de Penthrox® en Australia durante más de 30 años con efectos secundarios mínimos: mostrando Penthrox® un gran nivel de seguridad y eficacia.

Características técnicas

Disponibilidad:
  • Caja combinada simple (ME-MS245-MK2): Un recipiente de 3 ml de PENTHROX (metoxiflurano) en una caja con un inhalador PENTHROX – Disponible en cajas de 10
  • Caja combinada doble (ME-MS246-MK2): Dos recipientes de 3 ml de PENTHROX (metoxiflurano) en una caja con un inhalador PENTHROX – Disponible en cajas de 10
  • Caja combinada (ME-MS260-MK2): Un recipiente de 3 ml de PENTHROX (metoxiflurano) en una caja con un inhalador PENTHROX y una cámara de carbón activado (AC) – Disponible en unidades
  • Caja combinada (ME-MS260-10-MK2): Un recipiente de 3 ml de PENTHROX (metoxiflurano) en una caja con un inhalador PENTHROX y una cámara de carbón activado (AC) – Disponible en cajas de 10

Certificaciones:

Certificado Comunidad Europea

Ampliar informacion en el Enlace

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. Name of the medicinal product
PENTHROX 3mL inhalation vapour, liquid

2. Qualitative and quantitative composition
Each vial contains 3 mL of methoxyflurane 99.9%.

For full list of excipients see, section 6.1.

3. Pharmaceutical form
Inhalation vapour, liquid.

Clear, almost colourless, volatile liquid, with a characteristic fruity odour.

4. Clinical particulars
4.1 Therapeutic indications
Emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain. See sections 4.2 and 5.1.

4.2 Posology and method of administration
PENTHROX should be self-administered under supervision of a person trained in its administration, using the hand held PENTHROX Inhaler.

When to use PENTHROX


PENTHROX is suitable for your conscious adult patients reporting 4 or above on the pain scale.1



Adults

One bottle of 3 mL PENTHROX to be vaporised in a PENTHROX inhaler. On finishing the 3 mL dose, another 3 mL may be used. Dose of PENTHROX should not exceed 6 mL in a single administration. Methoxyflurane may cause renal failure if the recommended dose is exceeded. The lowest effective dosage of PENTHROX to provide analgesia should be used.

Onset of pain relief is rapid and occurs after 6 – 10 inhalations. Patients should be instructed to inhale intermittently to achieve adequate analgesia. Patients are able to assess their own level of pain and titrate the amount of PENTHROX inhaled for adequate pain control. Continuous inhalation provides analgesic relief for up to 25-30 minutes. Intermittent inhalation may provide longer analgesic relief. Patients should be advised to take the lowest possible dose to achieve pain relief.

The frequency at which PENTHROX can be safely used is not established. Administration on consecutive days is not recommended and the total dose to a patient in a week should not exceed 15 ml (see section 4.4).

Children

PENTHROX should not be used in children under 18 years.

Method of Administration

https://www.penthrox.co.uk/content/uploads/sites/2/2017/01/PEN-15-036-A3-How-to-Administer-Poster.pdf

Instructions on the preparation of the PENTHROX Inhaler and correct administration are provided in the Figures below.


1

Ensure the Activated Carbon (AC) Chamber is inserted into the dilutor hole on the top of the PENTHROX Inhaler.



2

Remove the cap of the bottle by hand. Alternatively, use the base of the PENTHROX Inhaler to loosen the cap with a ½ turn. Separate the Inhaler from the bottle and remove the cap by hand.



3

Tilt the PENTHROX Inhaler to a 45° angle and pour the total contents of one PENTHROX bottle into the base of the Inhaler whilst rotating.



4

Place wrist loop over patient's wrist. Patient inhales through the mouthpiece of the PENTHROX Inhaler to obtain analgesia. First few breaths should be gentle and then breathe normally through Inhaler.





5

Patient exhales into the PENTHROX Inhaler. The exhaled vapour passes through the AC Chamber to adsorb any exhaled methoxyflurane.



6

If stronger analgesia is required, patient can cover dilutor hole on the AC chamber with finger during use.



7

Patient should be instructed to inhale intermittently to achieve adequate analgesia. Continuous inhalation will reduce duration of use. Minimum dose to achieve analgesia should be administered.



8

Replace cap onto PENTHROX bottle. Place used PENTHROX Inhaler and used bottle in sealed plastic bag and dispose of responsibly.

How to administer Penthrox® (metoxiflurano)?

Healthcare professional administering PENTHROX must provide and explain the Product Information Leaflet to the patient.

4.3 Contraindications
Use as an anaesthetic agent.

Hypersensitivity to PENTHROX or any fluorinated anaesthetic.

Malignant hyperthermia: patients with known or genetically susceptible to malignant hyperthermia or a history of severe adverse reactions in either patient or relatives.

Patients who have a history of showing signs of liver damage after previous methoxyflurane use or halogenated hydrocarbon anaesthesia.

Clinically significant renal impairment.

Altered level of consciousness due to any cause including head injury, drugs, or alcohol.

Clinically evident cardiovascular instability.

Clinically evident respiratory depression.

4.4 Special warnings and precautions for use
Renal disease

Methoxyflurane causes significant nephrotoxicity at high doses. Nephrotoxicity is also related to the rate of metabolism. Therefore factors that increase the rate of metabolism such as drugs that induce hepatic enzymes can increase the risk of toxicity with methoxyflurane as well as sub-groups of people with genetic variations that may result in fast metaboliser status (see section 4.5). Nephrotoxicity is thought to be associated with inorganic fluoride ions, a metabolic break-down product. Toxicity in the past when used as an anaesthetic agent has been determined to be associated with serum levels greater than 40 μmol/L. Following a single dose of 3 mL serum levels did not exceed 10 μmol/L.

Despite this safety margin the lowest effective dose of methoxyflurane should be administered, especially in the elderly or patients with other known risk factors of renal disease. In addition, methoxyflurane should be cautiously used in patients diagnosed with clinical conditions that would pre-dispose to renal injury.

Liver disease

Methoxyflurane is metabolised in the liver, therefore increased exposures in patients with hepatic impairment can cause toxicity. PENTHROX must not be used in patients who have a history of showing signs of liver damage after previous methoxyflurane use or halogenated hydrocarbon anaesthesia. PENTHROX should be used with care in patients with underlying hepatic conditions or with risks for hepatic dysfunction (such as enzyme inducers - see also section 4.5).

It has been reported that previous exposure to halogenated hydrocarbon anaesthetics (including methoxyflurane when used in the past as an anaesthetic agent), especially if the interval is less than 3 months, may increase the potential for hepatic injury.

Cautious clinical judgement should be exercised when PENTHROX is to be used more frequently than on one occasion every 3 months.

Cardiovascular system depression / Use in elderly

Potential effects on blood pressure and heart rate are known class-effects of high dose methoxyflurane used in anaesthesia and other anaesthetics. They do not appear to be significant at the analgesic doses. There is no particular pattern to the patients' systolic BP levels after methoxyflurane administration as an analgesic across age groups. However, as the risk may potentially be increased for older people with hypotension and bradycardia, caution should be exercised in the elderly due to possible reduction in blood pressure.

Central nervous system effects

Secondary pharmacodynamic effects including potential CNS effects such as sedation, euphoria, amnesia, ability to concentrate, altered sensorimotor co-ordination and change in mood are also known class-effects. Self-administration of methoxyflurane in analgesic doses will be limited by occurrence of CNS effects, such as sedation.

Additionally, the CNS effects can be a risk factor for potential abuse.

Occupational exposure

Healthcare professionals who are regularly exposed to patients using PENTHROX inhalers should be aware of any relevant occupational health and safety guidelines for the use of inhalational agents. To reduce occupational exposure to methoxyflurane, the PENTHROX Inhaler should always be used with the Activated Carbon (AC) Chamber which adsorbs exhaled methoxyflurane. Multiple use of PENTHROX Inhaler without the AC Chamber creates additional risk. Elevation of liver enzymes, blood urea nitrogen and serum uric acid have been reported in exposed maternity ward staff in delivery wards when methoxyflurane was used in the past in obstetric patients at the time of labour and delivery.

Frequent repeated use

Due to the limitations on the dose of PENTHROX (maximum - 6ml) and the duration of pain relief, PENTHROX is not appropriate for providing relief of break-through pain/exacerbations in chronic pain conditions. PENTHROX is also not appropriate for relief of trauma related pain in closely repeated episodes for the same patient.

Butylated hydroxytoluene

PENTHROX contains the excipient, butylated hydroxytoluene (E321), a stabiliser. Butylated hydroxytoluene may cause local skin reactions (e.g. contact dermatitis), or irritation to the eyes and mucous membranes. See section 6.1.

4.5 Interaction with other medicinal products and other forms of interaction
The metabolism of methoxyflurane is mediated by the CYP 450 enzymes particularly CYP 2E1 and to some extent CYP 2A6. It is possible that enzyme inducers (such as alcohol or isoniazid for CYP 2E1 and phenobarbital or rifampicin for CYP 2A6) which increase the rate of methoxyflurane metabolism might increase its potential toxicity and they should be avoided concomitantly with methoxyflurane.

Concomitant use of PENTHROX with CNS depressants, such as opioids, sedatives or hypnotics, general anaesthetics, phenothiazines, tranquillisers, skeletal muscle relaxants, sedating antihistamines and alcohol may produce additive depressant effects. If opioids are given concomitantly with PENTHROX, the patient should be observed closely, as is normal clinical practice with opioids.

Concomitant use of methoxyflurane with medicines (e.g. contrast agents and some antibiotics) which are known to have a nephrotoxic effect should be avoided as there may be an additive effect on nephrotoxicity. Antibiotics with known nephrotoxic potential include tetracycline, gentamicin, colistin, polymyxin B and amphotericin B. It is advisable to avoid using sevoflurane anaesthesia following methoxyflurane analgesia, as sevoflurane increases serum fluoride levels and nephrotoxicity of methoxyflurane is associated with raised serum fluoride.

There are no reported drug interactions when used at the analgesic dosage (3 – 6 mL).

When methoxyflurane was used for anaesthesia at the higher doses of 40 – 60 mL, there were reports of:

a) Drug interaction with hepatic enzyme inducers (eg barbiturates) increasing metabolism of methoxyflurane and resulting in a few reported cases of nephrotoxicity. There is insufficient information to show whether enzyme induction affects liver damage after an analgesic dose of methoxyflurane.

b) Reduction of renal blood flow and hence anticipated enhanced renal effect when used in combination with drugs (eg barbiturates) reducing cardiac output.

c) Class effect on cardiac depression which may be enhanced by other cardiac depressant drugs, eg intravenous practolol during cardiac surgery.

4.6 Fertility, pregnancy and lactation
Fertility

No clinical data on effects of methoxyflurane on fertility are available. Limited data from animal studies do not indicate any effects on sperm morphology.

Pregnancy

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).

Where methoxyflurane has been used for obstetric analgesia in pregnant women, there has been a single report of neonatal respiratory depression associated with a high fetal level of methoxyflurane. However, when low concentrations were administered, or the duration of higher concentrations was kept short, per recommended posology, methoxyflurane was found to have little effect on the fetus. No fetal complications were reported to result from methoxyflurane analgesia in the mother in all the studies completed in obstetric analgesia.

As with all medicines care should be exercised when administered during pregnancy especially the first trimester.

Breast-feeding

There is insufficient information on the excretion of methoxyflurane in human milk. Caution should be exercised when methoxyflurane is administered to a nursing mother.

4.7 Effects on ability to drive and use machines
Methoxyflurane may have a minor influence on the ability to drive and use machines. Dizziness, somnolence and drowsiness may occur following the administration of methoxyflurane (see section 4.8). Patients should be advised not to drive or operate machinery if they are feeling drowsy or dizzy.

4.8 Undesirable effects
Summary of safety profile

The most common non-serious reactions are CNS type reactions such as dizziness, and somnolence (≥1/100 to <1 and="" are="" easily="" font="" generally="" reversible.="">

Serious dose-related nephrotoxicity has only been associated with methoxyflurane when used in large doses over prolonged periods during general anaesthesia. Methoxyflurane is therefore no longer used for anaesthesia. See section 4.4 under renal disease. The recommended maximum dose for PENTHROX should therefore not be exceeded.

Tabulated list of adverse reactions

The adverse drug reactions observed in PENTHROX clinical studies in analgesia are listed in the table below, classified according to frequency (common ≥1/100 to <1 font="" to="" uncommon="">

MedDRA System Organ Class

Common

≥1/100 to <1 font="">

Uncommon

≥1/1,000 to <1 font="">

Nervous system disorders

Amnesia

Anxiety

Depression

Dizziness

Dysarthria

Dysgeusia

Euphoria

Headache

Sensory neuropathy

Somnolence

Paraesthesia

Cardiac disorders

Hypotension

Eye disorders

Diplopia

Respiratory, thoracic and mediastinal disorders

Coughing

Gastrointestinal disorders

Dry mouth

Nausea

Oral discomfort

General disorders

Feeling drunk

Fatigue

Feeling abnormal

Increased appetite

Shivering

Skin and subcutaneous tissue disorders

Sweating

Post-marketing experience

Rare (≥1/10,000 to <1 analgesic="" been="" failure="" font="" have="" hepatic="" hepatitis="" methoxyflurane.="" observed="" of="" reports="" use="" with="">

Other events linked to the methoxyflurane use in analgesia (in addition to the reactions from clinical trials listed above), including reports from the literature include:

- Nervous system disorders: drowsiness, agitation, restlessness, dissociation, affect lability, disorientation, altered state of consciousness

- Respiratory system: choking, hypoxia, oxygen saturation decreased

- Cardiovascular system: blood pressure fluctuation

- Gastrointestinal: vomiting

- Hepatic: hepatitis, increased liver enzymes, jaundice, liver injury

- Renal: increased serum uric acid, urea nitrogen and creatinine, renal failure

- Eyes: blurred vision, nystagmus

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9 Overdose
Patients should be observed for signs of drowsiness, pallor and muscle relaxation following methoxyflurane administration.

High doses of methoxyflurane cause dose related nephrotoxicity. High output renal failure has occurred several hours or days after the administration of repeated high analgesic or anaesthetic doses of methoxyflurane.

5. Pharmacological properties
5.1 Pharmacodynamic properties
Pharmacodynamic effects

Methoxyflurane vapour provides analgesia when inhaled at low concentrations. After methoxyflurane administration, drowsiness may occur. During methoxyflurane administration, the cardiac rhythm is usually regular. The myocardium is only minimally sensitised to adrenaline by methoxyflurane. At analgesic therapeutic doses pain relief may lead to some decrease in blood pressure. This may be accompanied by bradycardia.

Clinical efficacy and safety

The efficacy and safety of PENTHROX was demonstrated in MEOF-001, a randomised, double-blind, multi-centre, placebo controlled study in the treatment of acute pain in patients with minor trauma presenting to an Emergency Department. 300 patients were recruited (149 received methoxyflurane and 149 received placebo in a 1:1 ratio). Patients with a pain score of ≥ 4 to ≤ 7 on the Numerical Rating Scale were eligible for the study. The mean pain scores (Visual Analogue Scale) observed at baseline were similar in the methoxyflurane (64.8) and placebo (64.0) groups. The primary efficacy variable, the estimated mean change in VAS pain from Baseline to 5 min, 10 min, 15 min and 20 min, was greater for the methoxyflurane group (-23.1, -28.9, -34.0 and -35.0 respectively) when compared to the placebo group (-11.3, -14.8, -15.5 and -19.0 respectively). Overall, there was a highly significant difference between the methoxyflurane and placebo group (estimated treatment effect -15.1; 95% CI -19.2 to -11.0; p<0 -18.5="" .0001="" 0.0001="" 1-10="" 10="" 126="" 15="" 20="" 30.9="" 30="" 33.6="" 37.6="" 57.7="" 5="" 63.8="" 76="" a="" after="" an="" analysis="" and="" as="" at="" baseline="" compared="" comparison="" defined="" each="" effect="" estimated="" experienced="" first="" font="" for="" from="" greater="" greatest="" group.="" group="" improvement="" in="" indicated="" inhalations="" least="" methoxyflurane="" mins="" minutes="" of="" p="" pain="" patient="" patients="" percentage="" placebo="" relief="" responder="" responders="" results="" score.="" seen="" significantly="" that="" the="" their="" this="" time-point.="" to="" total="" treatment="" undertaken="" vas="" was="" when="" where="" who="" with="">

5.2 Pharmacokinetic properties
Absorption

Methoxyflurane has the following partition coefficients:

• a water/gas coefficient of 4.5,

• a blood/gas coefficient of 13 and

• an oil/gas coefficient of 825

Methoxyflurane enters the lungs in the form of a vapour and is rapidly transported into the blood, therefore there is a rapid onset of analgesic action.

Distribution

Methoxyflurane has a high oil/gas coefficient hence methoxyflurane is highly lipophilic. Methoxyflurane has great propensity to diffuse into fatty tissues where it forms a reservoir from which it is released slowly over days.

Metabolism

Biotransformation of methoxyflurane occurs in man. Methoxyflurane is metabolised by dechlorination and o-demethylation in the liver, mediated by CYP 450 enzymes particularly CYP 2E1 and CYP 2A6. Methoxyflurane is metabolised to free fluoride, oxalic acid, difluoromethoxyacetic acid, and dichloroacetic acid. Both free fluoride and oxalic acid can cause renal damage at concentrations higher than those achievable with single analgesic dose use. Methoxyflurane is more susceptible to metabolism than other halogenated methyl ethyl ethers and has greater propensity to diffuse into fatty tissues. Hence methoxyflurane is released slowly from this reservoir and becomes available for biotransformation for many days.

Excretion

Approximately 60% of methoxyflurane uptake is excreted in the urine as organic fluorine, fluoride and oxalic acid; the remainder is exhaled unaltered or as carbon dioxide. Higher peak blood fluoride levels may be obtained earlier in obese than in non-obese people, and in the elderly.

5.3 Preclinical safety data
Embryo-fetal development

In studies in mice and rats, methoxyflurane crossed the placenta but demonstrated no evidence of embryotoxic or teratogenic properties. However, delayed fetal development (reduced fetal body weight and decreased ossification) was observed following repeated dosing over 9 days. The no observed adverse effect level (NOAEL) for embryo-fetal development was 0.006% - 4h/day in mice and close to 0.01% - 8 h/day in rats. The NOAELs in mouse and rat represent a 1- to 2-fold margin on a mg/kg basis and a 0.1- to 0.3-fold margin on a mg/m2 basis versus the proposed maximum clinical dose. As PENTHROX is not intended for daily use, the risk of delayed fetal development is considered to be very low.

Hepatic effects

Repeated intermittent or continuous administration of subanaesthetic concentrations of methoxyflurane has been associated with limited and commonly reversible hepatic changes (fatty metamorphosis, elevated ALT/AST) in several species. A NOAEL has not been established. These effects were seen at exposures considered sufficiently in excess of those anticipated through normal clinical use of the product.

6. Pharmaceutical particulars
6.1 List of excipients
Butylated hydroxytoluene E321 (stabiliser).

6.2 Incompatibilities
Not applicable.

6.3 Shelf life
36 months.

6.4 Special precautions for storage
This medicinal product does not require any special temperature storage conditions. For storage, PENTHROX combination pack should be kept in a locked cabinet, and should not be left on an open shelf.

6.5 Nature and contents of container
PENTHROX is supplied in the following presentations:

3 mL bottle with a tear off tamper-evident seal (packs of 10)

Combination pack with one 3 mL bottle, one PENTHROX Inhaler and one Activated Carbon (AC) chamber (packs of 1 or 10).

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling
After loading the PENTHROX Inhaler, replace cap onto PENTHROX bottle. After use, place used PENTHROX Inhaler and used bottle in plastic bag provided, seal and dispose of responsibly.

7. Marketing authorisation holder
Medical Developments UK Limited

c/o Price Bailey LLP

Causeway House

1 Dane Street, Bishop's Stortford

Herts CM23 3BT

United Kingdom

8. Marketing authorisation number(s)
PL 42467/0001

9. Date of first authorisation/renewal of the authorisation
27/10/2015

10. Date of revision of the text

22/12/2016

https://www.medicines.org.uk/emc/files/pil.1939.pdf

Penthrox Administration Checklist-HCP use


Penthrox Administration Checklist-HCP use Further copies of the educational materials and training on the administration of Penthrox are available from Galen on request (tel 028 38334974 or email customer.services@galen-pharma.com).

Penthrox Administration Guide-HCP use

Penthrox Administration Guide-HCP use Further copies of the educational materials and training on the administration of Penthrox are available from Galen on request (tel 028 38334974 or email customer.services@galen-pharma.com).

Penthrox Patient Alert Card-Patient Use

Penthrox Patient Alert Card-Patient Use


MANUAL DE ATENCIÓN AL PARTO EN EL ÁMBITO EXTRAHOSPITALARIO. Ministerio de Sanidad, Servicios Sociales e Igualdad. España


¿Qué es el parto velado "Parto Empelicado" o nacer con bolsa intacta? by NATALBEN.com



Balística de las heridas: introducción para los profesionales de la salud, del derecho, de las ciencias forenses, de las fuerzas armadas y de las fuerzas encargadas de hacer cumplir la ley http://emssolutionsint.blogspot.com/2017/04/balistica-de-las-heridas-introduccion.html
Guía para el manejo médico-quirúrgico de heridos en situación de conflicto armado by CICR http://emssolutionsint.blogspot.com/2017/09/guia-para-el-manejo-medico-quirurgico.html


CIRUGÍA DE GUERRA TRABAJAR CON RECURSOS LIMITADOS EN CONFLICTOS ARMADOS Y OTRAS SITUACIONES DE VIOLENCIA VOLUMEN 1 C. Giannou M. Baldan CICR http://emssolutionsint.blogspot.com.es/2013/01/cirugia-de-guerra-trabajar-con-recursos.html


Manual Suturas, Ligaduras, Nudos y Drenajes. Hospital Donostia, Pais Vasco. España http://emssolutionsint.blogspot.com/2017/09/manual-suturas-ligaduras-nudos-y.html


Técnicas de Suturas para Enfermería ASEPEYO y 7 tipos de suturas que tienen que conocer estudiantes de medicina http://emssolutionsint.blogspot.com/2015/01/tecnicas-de-suturas-para-enfermeria.html


Manual Práctico de Cirugía Menor. Grupo de Cirugia Menor y Dermatologia. Societat Valenciana de Medicina Familiar i Comunitaria http://emssolutionsint.blogspot.com/2013/09/manual-practico-de-cirugia-menor.html

Protocolo de Atencion para Cirugia. Ministerio de Salud Publica Rep. Dominicana. Marzo 2016 http://emssolutionsint.blogspot.com/2016/09/protocolo-de-atencion-para-cirugia.html
Manual de esterilización para centros de salud. Organización Panamericana de la Salud http://emssolutionsint.blogspot.com/2016/07/manual-de-esterilizacion-para-centros.html
Libre de Mantenimiento 
El mas ECONOMICO
Vendemos en España y Rep. Dominicana
Hacemos entrega del Sistema Completo

eeiispain@gmail.com

“UNA VIDA NO TIENE PRECIO”

TELEFUNKEN AED DISPONIBLE EN TODA AMERICA 6 AÑOS DE GARANTIA (ECONOMICO) http://goo.gl/JIYJwk

Follow me / INVITA A TUS AMIGOS A SEGUIRNOS

Contactos:  eeiispain@gmail.com
LinkeIn https://es.linkedin.com/in/drramonreyes
Twitter: @DrtoleteMD
Instagram: https://www.instagram.com/drtolete/



¿Por qué el Desfibrilador TELEFUNKEN?
El DESFIBRILADOR de Telefunken es un DESFIBRILADOR AUTOMÁTICO sumamente avanzado y muy fácil de manejar.
Fruto de más de 10 años de desarrollo, y avalado por TELEFUNKEN, fabricante con más de 80 años de historia en la fabricación de dispositivos electrónicos.
El desfibrilador TELEFUNKEN cuenta con las más exigentes certificaciones.
Realiza automáticamente autodiagnósticos diarios y mensuales.

Incluye bolsa y accesorios.
Dispone de electrodos de "ADULTO" y "PEDIÁTRICOS".
Tiene 6 años de garantía.
Componentes kit de emergencias
Máscarilla de respiración con conexión de oxígeno.
Tijeras para cortar la ropa
Rasuradora.
Guantes desechables.

¿ Qué es una Parada Cardíaca?
Cada año solo en paises como España mueren más de 25.000 personas por muerte súbita.
La mayoría en entornos extrahospitalarios, y casi el 80-90 % ocasionadas por un trastorno eléctrico del corazón llamado"FIBRILACIÓN VENTRICULAR"

El único tratamiento efectivo en estos casos es la "Desfibrilación precoz".
"Por cada minuto de retraso en realizar la desfibrilación, las posibilidades de supervivencia disminuyen en más de un 10%".

¿ Qué es un desfibrilador ?
El desfibrilador semiautomático (DESA) es un pequeño aparato que se conecta a la víctima que supuestamente ha sufrido una parada cardíaca por medio de parches (electrodos adhesivos).

¿ Cómo funciona ?

SU FUNDAMENTO ES SENCILLO:
El DESA "Desfibrilador" analiza automáticamente el ritmo del corazón. Si identifica un ritmo de parada cardíaca tratable mediante la desfibrilación ( fibrilación ventricular), recomendará una descarga y deberá realizarse la misma pulsando un botón.

SU USO ES FÁCIL:
El desfibrilador va guiando al reanimador durante todo el proceso, por medio de mensajes de voz, realizando las órdenes paso a paso.

SU USO ES SEGURO:
Únicamente si detecta este ritmo de parada desfibrilable (FV) y (Taquicardia Ventricular sin Pulso) permite la aplicación de la descarga. (Si por ejemplo nos encontrásemos ante una víctima inconsciente que únicamente ha sufrido un desmayo, el desfibrilador no permitiría nunca aplicar una descarga).

¿Quién puede usar un desfibrilador TELEFUNKEN?
No es necesario que el reanimador sea médico, Enfermero o Tecnico en Emergencias Sanitarias para poder utilizar el desfibrilador.

Cualquier persona (no médico) que haya superado un curso de formación específico impartido por un centro homologado y acreditado estará capacitado y legalmente autorizado para utilizar el DESFIBRILADOR (En nuestro caso la certificacion es de validez mundial por seguir los protolos internacionales del ILCOR International Liaison Committee on Resuscitation. y Una institucion de prestigio internacional que avale que se han seguido los procedimientos tanto de formacion, ademas de los lineamientos del fabricante como es el caso de eeii.edu

TELEFUNKEN en Rep. Dominicana es parte de Emergency Educational Training Institute de Florida. Estados Unidos, siendo Centro de Entrenamiento Autorizado por la American Heart Association y American Safety and Health Institute (Por lo que podemos certificar ILCOR) Acreditacion con validez en todo el mundo y al mismo tiempo certificar el lugar en donde son colocados nuestros Desfibriladores como Centros Cardioprotegidos que cumplen con todos los estanderes tanto Europeos CE como de Estados Unidos y Canada
DATOS TÉCNICOS
Dimensiones: 220 x 275 x 85mm
Peso: 2,6 Kg.
Clase de equipo: IIb
ESPECIFICACIONES
Temperatura: 0° C – + 50° C (sin electrodos)
Presión: 800 – 1060 hPa
Humedad: 0% – 95%
Máximo Grado de protección contra la humedad: IP 55
Máximo grado de protección contra golpes:IEC 601-1:1988+A1:1991+A2:1995
Tiempo en espera de las baterías: 3 años (Deben de ser cambiadas para garantizar un servicio optimo del aparato a los 3 años de uso)
Tiempo en espera de los electrodos: 3 años (Recomendamos sustitucion para mantener estandares internacionales de calidad)
Número de choques: >200
Capacidad de monitorización: > 20 horas (Significa que con una sola bateria tienes 20 horas de monitorizacion continua del paciente en caso de desastre, es optimo por el tiempo que podemos permanecer en monitorizacion del paciente posterior a la reanimacion)
Tiempo análisis ECG: < 10 segundos (En menos de 10 seg. TELEFUNKEN AED, ha hecho el diagnostico y estara listo para suministrar tratamiento de forma automatica)
Ciclo análisis + preparación del shock: < 15 segundos
Botón información: Informa sobre el tiempo de uso y el número de descargas administradas durante el evento con sólo pulsar un botón
Claras señales acústicas y visuales: guía por voz y mediante señales luminosas al reanimador durante todo el proceso de reanimación.
Metrónomo: que indica la frecuencia correcta para las compresiones torácicas. con las Guias 2015-2020, esto garantiza que al seguir el ritmo pautado de compresiones que nos indica el aparato de forma acustica y visual, podremos dar RCP de ALTA calidad con un aparato extremadamente moderno, pero economico.
Normas aplicadas: EN 60601-1:2006, EN 60601-1-4:1996, EN 60601-1:2007, EN 60601-2-4:2003
Sensibilidad y precisión:
Sensibilidad > 90%, tip. 98%,
Especificidad > 95%, tip. 96%,
Asistolia umbral < ±80μV
Protocolo de reanimación: ILCOR 2015-2020
Análisis ECG: Ritmos cardiacos tratables (VF, VT rápida), Ritmos cardiacos no tratables (asistolia, NSR, etc.)
Control de impedancia: Medición9 de la impedancia continua, detección de movimiento, detección de respiración
Control de los electrodos : Calidad del contacto
Identificación de ritmo normal de marcapasos
Lenguas: Holandés, inglés, alemán, francés, español, sueco, danés, noruega, italiano, ruso, chino
Comunicación-interfaz: USB 2.0 (El mas simple y economico del mercado)
Usuarios-interfaz: Operación de tres botones (botón de encendido/apagado , botón de choque/información.
Indicación LED: para el estado del proceso de reanimación. (Para ambientes ruidosos y en caso de personas con limitaciones acusticas)
Impulso-desfibrilación: Bifásico (Bajo Nivel de Energia, pero mayor calidad que causa menos daño al musculo cardiaco), tensión controlada
Energía de choque máxima: Energía Alta 300J (impedancia de paciente 75Ω), Energía Baja 200J
(impedancia de paciente 100Ω)


Medical Doctor for complex and high-risk missions
+34 671 45 40 59
        
Medicina Bona Locis Malis
EU Medical Doctor / Spain 05 21 04184
Advanced Prehospital Trauma Life Support /Tactical Combat Casualty Care TCCC Instructor and Faculty 
ACLS EP / PALS American Heart Association and European Resucitation Council Instructor and Faculty
Member SOMA Special Operational Medical Association ID Nº 17479 
Corresponding Member Dominican College of Surgeons Book 1  Page M H10
Member Spanish Society of Emergency Medicine SEMES
DMO Diving Medical Officer- USA
Air Medical Crew Instructor DOT- USA
Tactical Medical Specialist and Protective Medicine -USA
TECC Tactical Emergency Casualty Care Faculty and Medical Director by C-TECC
MLinkedIn 
Ask about TELEFUNKEN AED